Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive ...
2don MSN
Seattle’s Alpenglow moves 3D microscope tech from lab to clinic to help modernize cancer diagnostics
Alpenglow Biosciences announced a partnership with PathNet to help commercialize use of the startup's 3D microscope ...
Applications are invited for recruitment of 13 vacant positions or career in LGBRIMH Tezpur Assam in 2026. Lokapriya Gopinath Bordoloi Region ...
News Medical on MSN
Autism research reframed: Why heterogeneity is the data, not the noise
Dr. Noritaka Ichinohe discusses three decades of translational neuroscience in a new Genomic Press Interview. His work links ...
A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...
Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...
OpenAI continues its push into healthcare with the launch of ChatGPT Health, a new feature that connects its artificial ...
Health eCareers on MSN
Thriving in hybrid medicine careers: Balancing clinical practice with nonclinical roles
Medicine is no longer a one-track career. As workforce burnout, digital medicine, and changing financial pressures continue ...
FITBOOK magazine on MSN
The biggest misconception about the weight-loss injection
The GLP-1 injection as a shortcut to the desired weight–what many now consider a lifestyle drug is actually a prescription ...
Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...
Six trends are reshaping women’s health investing—from new funds and capital vehicles to rising demand and platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback